On August 5, 2024, Three Clover Biopharmaceutical Co. Ltd. ("Three Clover Biopharmaceutical-B") submitted the latest monthly securities report to Hong Kong Exchanges and Clearing Limited, reporting on the company's shareholding changes as of July 31, 2024. The report shows that the company's statutory/registered capital and issued shares (excluding treasury shares) did not change in the month and remained at 2,000,000,000 ordinary shares with a par value of $0.0001, with a total statutory/registered capital of $200,000 and a total number of issued shares of 1,297,048,929. In addition, there was no change in the number of share options for the company's share option plan before and after the initial public offering, and there were no options exercised or expired. The company confirms that all securities issuance or treasury share sales or transfers have been authorized by the board of directors and comply with relevant regulations.

On August 5, 2024, Three Clover Biopharmaceutical Co. Ltd. ("Three Clover Biopharmaceutical-B") submitted the latest monthly securities report to Hong Kong Exchanges and Clearing Limited, reporting on the company's shareholding changes as of July 31, 2024. The report shows that the company's statutory/registered capital and issued shares (excluding treasury shares) did not change in the month and remained at 2,000,000,000 ordinary shares with a par value of $0.0001, with a total statutory/registered capital of $200,000 and a total number of issued shares of 1,297,048,929. In addition, there was no change in the number of share options for the company's share option plan before and after the initial public offering, and there were no options exercised or expired. The company confirms that all securities issuance or treasury share sales or transfers have been authorized by the board of directors and comply with relevant regulations.